J&J on gainsharing
This article was originally published in The Gray Sheet
Executive Summary
CFO Robert Darretta tells investors during April 19 earnings call that the strategy by which some hospitals curb the cost of devices purchased - allowing doctors to share in the savings - is "something [the firm is] monitoring and, I am sure, we will have conversations about it in the future" (1"The Gray Sheet" April 11, 2005, p. 14). He added: "I am not sure about how [regulators] will feel about endorsing it [or] what length of time gains might be shared and among whom and how. Those things will have a significant impact on people's receptivity to the concept"...
You may also be interested in...
Ortho Firms Feel DoJ Probe Price As Stocks Fall In Q1; Will Zimmer Diversify?
The federal government's mounting scrutiny of orthopedic industry pricing practices for hip and knee replacement implants could convince Zimmer to more aggressively seek a presence in the artificial disc arena
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.